Physician profile
David Casper
NPI 1164614004
$1,559.81
in general payments reported to CMS, 2019-2025
23 companies · $96.92 in 2025
The $96.92 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $168 · 2021: $169 · 2022: $220 · 2023: $503 · 2024: $115 · 2025: $96.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $715.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $219.68 | 2019-2025 | Skyrizi |
| Galderma Laboratories, L.P. | $215.41 | 2021-2023 | Epsolay, Aklief |
| Novartis Pharmaceuticals Corporation | $154.15 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $132.77 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $111.32 | 2022-2023 | Sotyktu |
| Pfizer INC. | $90.80 | 2022-2023 | |
| Lilly USA, LLC | $82.79 | 2019-2024 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.86 | 2022-2025 | Spevigo |
| Genzyme Corporation | $57.04 | 2021-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $52.68 | 2021-2023 | Valchlor |
| Amgen INC. | $47.15 | 2019-2024 | Otezla |
| Dusa Pharmaceuticals, INC. | $41.59 | 2019 | |
| Organogenesis INC. | $41.10 | 2020-2021 | |
| Kerecis Limited | $39.83 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Regeneron Healthcare Solutions, INC. | $39.20 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $28.25 | 2023 | |
| Allergan, INC. | $24.30 | 2020 | |
| Organon LLC | $22.36 | 2025 | |
| Biofrontera INC. | $20.88 | 2024 | Ameluz, Rhodoled Xl, Xepi |
| Janssen Biotech, INC. | $18.11 | 2021 | |
| Boston Scientific Corporation | $16.22 | 2023 | Varithena Administration Pack |
| Merz North America, INC. | $15.88 | 2019 | |
| Medtronic, INC. | $12.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Casper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.